Status:
COMPLETED
Research Of Quality Of Life And Safety Outcomes Of Postmenopausal Breast Cancer Patients Switching From Tamoxifen Therapy To Aromatase Inhibitor Therapy
Lead Sponsor:
Pfizer
Conditions:
Breast Neoplasms
Eligibility:
FEMALE
40+ years
Brief Summary
The purpose of this study is to follow safety and quality of life outcomes on patients switching from tamoxifen therapy to aromatase inhibitor therapy.
Detailed Description
Group of patients using the same aromatase inhibitor
Eligibility Criteria
Inclusion
- Patients with endocrine responsive early stage postmenopausal breast cancer. Patients who received tamoxifen for 2-3 years as adjuvant endocrine therapy. Patients who were approved to switch to aromatase inhibitor treatment during the patient recruitment period.
- Patients who were informed about the study and accepted to participate.
Exclusion
- Patients having a psychological disorder which will prevent their understanding of questionnaires used for evaluation of quality of life and / or patients who are illiterate.
Key Trial Info
Start Date :
June 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
344 Patients enrolled
Trial Details
Trial ID
NCT00784888
Start Date
June 1 2008
End Date
December 1 2011
Last Update
March 15 2012
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Adana, Turkey (Türkiye), 01330
2
Pfizer Investigational Site
Ankara, Turkey (Türkiye), 06100
3
Pfizer Investigational Site
Ankara, Turkey (Türkiye), 06590
4
Pfizer Investigational Site
Ankara, Turkey (Türkiye)